Evidence map›Paper›PMID 39382167›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

Specific Requirement of the p84/p110γ Complex of PI3Kγ for Antibody-Activated, Inducible Cross-Presentation in Murine Type 2 DCs.

Despoina Koumantou, Aimé Cézaire Adiko, Pierre Bourdely, Mathilde Nugue, Erwan Boedec, Jamel El-Benna, Renato Monteiro, Cosmin Saveanu, Muriel Laffargue, Matthias P Wymann and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Targeting PI3Kγ in cancer.Trends in cancer · 2025
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Despoina KoumantouCentre de Recherche sur l'Inflammation, INSERM UMR1149, CNRS EMR8252, Faculté de Médecine site Bichat, Université Paris Cité, Paris, 75018, France.
Aimé Cézaire AdikoCentre de Recherche sur l'Inflammation, INSERM UMR1149, CNRS EMR8252, Faculté de Médecine site Bichat, Université Paris Cité, Paris, 75018, France.
Pierre BourdelyCentre de Recherche sur l'Inflammation, INSERM UMR1149, CNRS EMR8252, Faculté de Médecine site Bichat, Université Paris Cité, Paris, 75018, France.
Mathilde NugueCentre de Recherche sur l'Inflammation, INSERM UMR1149, CNRS EMR8252, Faculté de Médecine site Bichat, Université Paris Cité, Paris, 75018, France.
Erwan BoedecCentre de Recherche sur l'Inflammation, INSERM UMR1149, CNRS EMR8252, Faculté de Médecine site Bichat, Université Paris Cité, Paris, 75018, France.
Jamel El-BennaCentre de Recherche sur l'Inflammation, INSERM UMR1149, CNRS EMR8252, Faculté de Médecine site Bichat, Université Paris Cité, Paris, 75018, France.
Renato MonteiroCentre de Recherche sur l'Inflammation, INSERM UMR1149, CNRS EMR8252, Faculté de Médecine site Bichat, Université Paris Cité, Paris, 75018, France.
Cosmin SaveanuInstitut Pasteur, RNA Biology of Fungal Pathogens, Université Paris Cité, Paris, 75015, France.
Muriel LaffargueINSERM UMR 1048, I2MC, Toulouse, 4 31432, France.
Matthias P WymannDepartment of Biomedicine, University of Basel, Mattenstrasse 28, Basel, CH-4058, Switzerland.
Marc DalodCNRS, INSERM, CIML, Centre d'Immunologie de Marseille-Luminy, Turing Center for Living Systems, Aix-Marseille University, Marseille, 13007, France.
Pierre Guermonprez"Dendritic cells and adaptive immunity", Immunology department, Pasteur Institute, Paris, 75015, France.
Loredana SaveanuCentre de Recherche sur l'Inflammation, INSERM UMR1149, CNRS EMR8252, Faculté de Médecine site Bichat, Université Paris Cité, Paris, 75018, France.ORCID 0000-0003-3138-7968

Funding

Agence Nationale de la Recherche ANR-11-IDEX-0005-02Agence Nationale de la Recherche ANR-15-CE15-0005Agence Nationale de la Recherche ANR-17-CE11-0001Fondation pour la Recherche MedicaleICGex NGS platform of the Institut Curie ANR-10-EQPX-03ICGex NGS platform of the Institut Curie ANR-10-INBS-09-08SiRIC-Curie program INCa-DGOS-465SiRIC-Curie program INCa-DGOS- Inserm_12554Swiss National Science Foundation SNF-310030-189065
6 · The paper itself

Abstract

Cross-presentation by MHCI is optimally efficient in type 1 dendritic cells (DC) due to their high capacity for antigen processing. However, through specific pathways, other DCs, such as type 2 DCs and inflammatory DCs (iDCs) can also cross-present antigens. FcγR-mediated uptake by type 2 DC and iDC subsets mediates antibody-dependent cross-presentation and activation of CD8

Indexed as

Cross-PrimingDendritic CellsMice, Inbred C57BLAnimalsAntigen PresentationClass Ib Phosphatidylinositol 3-KinaseMiceClass Ib Phosphatidylinositol 3-KinasePik3cg protein, mouseantigen cross‐presentationdendritic cellsimmune complexesPI3K

Identifiers

PMID39382167
PMCPMC11600261

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.